Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,272.00+0.61%ETH$2,513.93+2.68%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
LB

NASDAQ · LBRX

LB Pharmaceuticals Inc Common Stock

Healthcare · Biotechnology

$46.25

Down-$1.62 (-3.50%)

Updated Sep 11, 2026, 11:32 PM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
508.76M
P/E ratio
-1.13
Dividend yield
0.00%
52-week range
$22.48 – $50.16
Volume
174.79K
Avg. volume
224.27K

Price performance

LBRX price history

1M range · 0 trading sessions · Daily adjusted prices

LBRX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LBRX news

The latest Smart Investors Daily articles mentioning LBRX.

Stock researchCompany · Overview

LBRX research

Overview

Company profile and research snapshot.

Company profile

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$34.50
Implied upside
—
Analysts
—
LBRX recent ratings
DateFirmRatingTarget
Aug 24, 2026HC Wainwright & Co.Buy—
Aug 12, 2026BMO CapitalOutperform—
Aug 3, 2026HC Wainwright & Co.Buy—
Jul 21, 2026BMO CapitalOutperform—
Jul 7, 2026Wolfe ResearchOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment

LB Pharmaceuticals (LBRX) has drawn fresh investor attention after appointing Joseph M. Miller as Chief Financial Officer. The announcement coincides with preparations for NOVA-2 trial readouts and a potential LB-102 launch in schizophrenia. Despite a pullback over the last day with a 1-day share price return of down 3.96% to US$47.52, LB Pharmaceuticals has delivered a 66.56% 90-day share price return and a 132.49% year-to-date share price return, which suggests that momentum has been...

Yahoo · Sep 3, 2026

LB Pharmaceuticals to Participate in Upcoming September Investor Events

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference 1x1 investor meetings on Wednesday, Septe

Yahoo · Sep 3, 2026

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer. Mr. Miller is a biopharmaceutical finance executive with more than two decades of experience leading financial strategy and operations and

Benzinga · Sep 3, 2026

LB Pharmaceuticals Appoints Joseph Miller CFO

LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By